Experts Discuss Use Of New TB Drug Bedaquiline

Global Health Technologies Coalition’s “Breakthroughs”: New TB drug bedaquiline: Weighing the benefits against the risks
The blog interviews Laia Ruiz Mingote and Dorothy Namutamba, co-chairs of the Community Research Advisors Group (CRAG), and Mike Watson Frick, the TB/HIV program officer at the Treatment Action Group, about the benefits and risks of using the new drug bedaquiline to treat TB (Chmiola, 8/20).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.